CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Meghann Wheeler; Julie W. Merten; Benjamin T Gordon; Hanadi Hamadi

doi:10.1080/10826084.2020.1729201

CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Meghann Wheeler, Julie W. Merten, Benjamin T Gordon, Hanadi Hamadi

University of North Florida

Producción científica: Article › revisión exhaustiva

Resumen

Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

Idioma original	American English
Publicación	Substance Use & Misuse
Volumen	55
DOI	https://doi.org/10.1080/10826084.2020.1729201
Estado	Published - feb 24 2020

Disciplines

Medicine and Health Sciences
Public Health
Family Medicine

Acceder al documento

10.1080/10826084.2020.1729201Licencia: Unspecified

Otros archivos y enlaces

Link to publication

Citar esto

@article{e21bd14f518c4fa59c22a5dff031f506,

title = "CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.",

abstract = "Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.",

author = "Meghann Wheeler and Merten, {Julie W.} and Gordon, {Benjamin T} and Hanadi Hamadi",

year = "2020",

month = feb,

day = "24",

doi = "10.1080/10826084.2020.1729201",

language = "American English",

volume = "55",

journal = "Substance Use & Misuse",

issn = "1082-6084",

}

TY - JOUR

T1 - CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

AU - Wheeler, Meghann

AU - Merten, Julie W.

AU - Gordon, Benjamin T

AU - Hamadi, Hanadi

PY - 2020/2/24

Y1 - 2020/2/24

N2 - Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

AB - Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

UR - https://doi.org/10.1080/10826084.2020.1729201

U2 - 10.1080/10826084.2020.1729201

DO - 10.1080/10826084.2020.1729201

M3 - Article

SN - 1082-6084

VL - 55

JO - Substance Use & Misuse

JF - Substance Use & Misuse

ER -